Psoriasis: challenges, therapeutic advances, and perspectives in the treatment of a chronic inflammatory disease
DOI:
https://doi.org/10.71068/ec000031Keywords:
Psoriasis, Chronic inflammatory disease, Biological treatment, Dermatological therapiesAbstract
Psoriasis is a chronic, inflammatory skin disease that affects between 2 and 3% of the world's population. This condition is characterized by a dysfunction of the immune system that causes abnormal cell growth in the epidermis, resulting in the formation of thick, red, scaly plaques on various areas of the body, especially the elbows, knees, and scalp. Although the exact cause of psoriasis is not yet fully understood, it is believed to result from a complex interaction between genetic and environmental factors. Research has shown that genetic predisposition plays a key role in the development of the disease, as multiple genes are associated with psoriasis, especially those related to the immune system, such as genes that code for pro-inflammatory cytokines. In addition to genetic factors, various environmental factors can trigger or aggravate psoriasis in predisposed individuals. These factors include stress, infections, cold and dry weather, the use of certain medications, and alcohol consumption. Advances in research in recent years have allowed a deeper understanding of the underlying immunological mechanisms, highlighting the involvement of T cells and inflammatory cytokines, which has expanded our understanding of the pathophysiology of the disease. The characteristic cutaneous lesions of psoriasis include well-demarcated plaques of thickened skin, scaling, and redness, and can vary in severity, from mild forms affecting limited areas of the skin to severe forms that involve large areas of the body and impact patients' quality of life. In addition to cutaneous manifestations, psoriasis is often associated with systemic inflammatory diseases, one of the most common being psoriatic arthritis. This inflammatory joint disease can cause pain, stiffness, and joint damage, increasing the disease burden for patients. The identification of molecular signaling pathways involved in the pathogenesis of psoriasis has revolutionized the treatment of the disease.
Downloads
References
1. Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. International Journal of Molecular Sciences. 2019;20(6):1475. https://doi.org/10.3390/ijms20061475.
2. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: A review. JAMA. 2021;325(7):669-678. https://doi.org/10.1001/jama.2020.23644.
3. Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, Gottlieb AB, Gisondi P, Wu JJ, Thyssen JP, Egeberg A. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. Journal of the American Academy of Dermatology. 2019;80(1):251-265. e19. https://doi.org/10.1016/j.jaad.2018.06.027.
4. Puig L, Thom H, Mollon P, Tian H, Ramakrishna GS. Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: A systematic review and meta-analysis. Journal of the European Academy of Dermatology and Venereology. 2017;31(2):213-220. https://doi.org/10.1111/jdv.14007.
5. Branisteanu DE, Nicolescu AC, Branisteanu DC, Branisteanu CI, Dragoi AC, Bogdanici CM, Toader MP, Tucaliuc AL, Dimitriu A, Daogaru D, Pirvulescu RA, Porumb EA. Cardiovascular comorbidities in psoriasis. Experimental and Therapeutic Medicine. 2022;23(2):152. https://doi.org/10.3892/etm.2021.11075.
6. Aune D, Snekvik I, Schlesinger S, Norat T, Riboli E, Vatten LJ. Body mass index, abdominal fatness, weight gain and the risk of psoriasis: A systematic review and dose-response meta-analysis of prospective studies. European Journal of Epidemiology. 2018;33(12):1163-1178. https://doi.org/10.1007/s10654-018-0366-z.
7. Mamizadeh M, Tardeh Z, Azami M. The association between psoriasis and diabetes mellitus: A systematic review and meta-analysis. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2019;13(2):1405-1412. https://doi.org/10.1016/j.dsx.2019.01.009.
8. Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. Journal of Investigative Dermatology. 2013;133(2):377-385. https://doi.org/10.1038/jid.2012.339.
9. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. Journal of the European Academy of Dermatology and Venereology. 2017;31(2):205-212. https://doi.org/10.1111/jdv.13854.
10. Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of psoriasis. Annual Review of Immunology. 2014;32:227-255. https://doi.org/10.1146/annurev-immunol-032713-120225.
11. AlQassimi S, AlBrashdi S, Galadari H, Hashim MJ. Global burden of psoriasis: Comparison of regional and global epidemiology, 1990 to 2017. International Journal of Dermatology. 2020;59(5):566-571. https://doi.org/10.1111/ijd.14864.
12. Yamazaki F. Psoriasis: Comorbidities. The Journal of Dermatology. 2021;48(6):732-740. https://doi.org/10.1111/1346-8138.15840.
13. Menter A, Gelfand JM, Connor C, Armstrong AW, Cordoro KM, Davis DMR, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Elmets CA. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. Journal of the American Academy of Dermatology. 2020;82(6):1445-1486. https://doi.org/10.1016/j.jaad.2020.02.044.
14. Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Elmets CA. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. Journal of the American Academy of Dermatology. 2019;80(4):1029-1072. https://doi.org/10.1016/j.jaad.2018.11.057.
15. Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Csörgö Z, Boonen H, De Jong E, Garcia-Doval I, Gisondi P, Kaur-Knudsen D, Mahil S, Mälkönen T, Maul JT, Mburu S, Mrowietz U, Reich K, Remenyik E, Rønholt KM, Sator PG, Dressler C. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris: Part 1. Journal of the European Academy of Dermatology and Venereology. 2020;34(11):2461-2498. https://doi.org/10.1111/jdv.16915.
16. Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Canadian Family Physician. 2020;66(2):121-127. https://www.cfp.ca/content/66/2/121.
17. Elmets CA, Korman NJ, Prater EF, Wong EB, Rupani RN, Kivelevitch D, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kroshinsky D, Lebwohl M, Menter A. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities. Journal of the American Academy of Dermatology. 2021;84(2):432-470. https://doi.org/10.1016/j.jaad.2020.07.087.
18. Alinaghi F, Tekin HG, Burisch J, Wu JJ, Thyssen JP, Egeberg A. Global prevalence and bidirectional association between psoriasis and inflammatory bowel disease: A systematic review and meta-analysis. Journal of Crohn’s and Colitis. 2020;14(3):351-360. https://doi.org/10.1093/ecco-jcc/jjz152.
19. Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States. JAMA Dermatology. 2013;149(10):1180-1185. https://doi.org/10.1001/jamadermatol.2013.5264.
20. De Luca DA, Papara C, Hawro T, Thaçi D. Psoriasis and diabetes: A review of the pathophysiological and therapeutic interconnections. Minerva Medica. 2025;116(3):195-222. https://doi.org/10.23736/S0026-4806.24.09570-3.
21. Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, Armstrong AW, Connor C, Cordoro KM, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kivelevitch D, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Menter A. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. Journal of the American Academy of Dermatology. 2019;80(4):1073-1113. https://doi.org/10.1016/j.jaad.2018.11.058.
22. Kommoss KS, Enk A, Heikenwälder M, Waisman A, Karbach S, Wild J. Cardiovascular comorbidity in psoriasis: Psoriatic inflammation is more than just skin deep. Journal der Deutschen Dermatologischen Gesellschaft. 2023;21(7):718-725. https://doi.org/10.1111/ddg.15071.
23. Lembke S, Macfarlane GJ, Jones GT. The worldwide prevalence of psoriatic arthritis: A systematic review and meta-analysis. Rheumatology. 2024;63(12):3211-3220. https://doi.org/10.1093/rheumatology/keae198.
24. Pérez-Chada LM, Hopkins ZH, Balak DMW, Rashid S, Creadore A, Chu B, Villa C, Woodbury MJ, Armstrong AW, Strand V, Gottlieb AB, Merola JF, Barbieri JS. Patient-reported outcome measures for health-related quality of life in patients with psoriasis: A systematic review. JAMA Dermatology. 2024;160(5):550-563. https://doi.org/10.1001/jamadermatol.2023.5439.
25. Phan K, Onggo J, Charlton O, Smith SD. Relationship between psoriasis and non-alcoholic fatty liver disease: Updated systematic review and adjusted meta-analysis. Australasian Journal of Dermatology. 2019;60(4):e352-e355. https://doi.org/10.1111/ajd.13015.
26. Wang M, Sun Y, Sun Y. Efficacy and safety of drugs for psoriasis patients with mental disorders: A systematic review. Journal of Affective Disorders. 2024;365:112-125. https://doi.org/10.1016/j.jad.2024.08.077.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 María Fernanda Espinoza Espinoza
This work is licensed under a Creative Commons Attribution 4.0 International License.
